ASCO 2023 | RedirecTT-1 results: teclistamab + talquetamab in R/R multiple myeloma
Yael Cohen, MD, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, shares the results of the Phase Ib RedirecTT-1 trial (NCT04586426) evaluating the combination of talquetamab and teclistamab in patients with heavily pretreated multiple myeloma. Dr Cohen notes that this combination did not lead to additive toxicity beyond that of monotherapy, and explains that most side effects were low-grade and manageable. Patients experienced an unprecedented overall response rate (ORR) of 92% at the recommended Phase II regimen (RP2R). In addition, this combination appeared to be particularly promising in patients with soft tissue plasmacytoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
